Company News

Sun Pharmaceuticals Industries gets approval for new label for Odomzo®

Sun Pharmaceuticals Industries has received approval from the
US Food and Drug Administration (USFDA) for a new label for Odomzo® (sonidegib), an oral hedgehog inhibitor indicated for the treatment of patients with locally advanced basal cell carcinoma (laBCC) that
has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

Odomzo® was approved by the FDA in July 2015, based on 12-month follow-up results from the pivotal Phase II Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) clinical trial, a multicenter,
double-blind study involving 194 patients with laBCC and 36 patients with metastatic basal cell carcinoma (mBCC). The new label now incorporates long-term data from the 30-month analysis of BOLT trial, in which Odomzo® continued to show sustained durable tumor response of 26 months with no new safety concerns.

Submission of Newspaper advertisement under Regulation 30 read with
Regulation 47 of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30 read
with Schedule III and Regulation 47 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015, we
have published an advertisement, regarding
i) Notice of the 25th Annual General Meeting of the Company to be held on
Tuesday, September 26, 2017 for the financial year
2016-17, ii) E-voting and iii) Book Closure, in all the editions of
Financial Express dated September 04, 2017 and in
Ahmedabad Edition (Gujarati Language) of Financial Express dated September
04, 2017. We are enclosing herewith copy of the
advertisement published in the following newspapers: 1. Financial Express
dated September 04, 2017- Mumbai Edition 2.
Financial Express dated September 04, 2017- Ahmedabad Edition 3. Financial
Express dated September 04, 2017- Ahmedabad
Edition (Gujarati Language)

Sun Pharmaceutical Industries Limited has informed the Exchange that
the
Register of Members and Share Transfer Books of the Company shall remain
closed from September 20, 2017 to September 26 , 2017(both days inclusive)
for the purpose of Annual General Meeting of the Company is scheduled to be
held on September 26, 2017.and Payment of dividend

Approval of Scheme of Arrangement among Sun Pharma Medisales Private
Limited, Ranbaxy Drugs Limited, Gufic Pharma Limited,
Vidyut Investments Limited and the Company and their respective members and
creditors from National Company Law Tribunal